Regulation of In Vivo CAR‑T Therapies

Introduction

In vivo CAR‑T therapy represents one of the most scientifically disruptive developments in modern biotechnology.

Unlike traditional CAR‑T therapies, where T cells are removed from the patient, genetically engineered ex vivo, expanded, and reinfused, in vivo CAR‑T platforms aim to genetically program immune cells directly inside the patient using viral vectors, lipid nanoparticles, or other targeted delivery systems.

As a result, regulators globally are now facing a major challenge: how to regulate therapies that blur the boundaries between traditional product categories while carrying highly potent and potentially long‑lasting biological activity.

Although no globally harmonised regulatory framework exists specifically for in vivo CAR‑T therapies, regulators including the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and other advanced regulatory agencies are rapidly evolving their approaches to these technologies.

Why In Vivo CAR‑T Creates Regulatory Complexity

Traditional CAR‑T products are relatively well-defined from a regulatory perspective. Cells are collected, engineered, characterised, released, and administered as a controlled cellular product.

In vivo CAR‑T fundamentally changes this paradigm.

Rather than manufacturing a defined cellular product externally, the therapeutic engineering process occurs dynamically inside the patient following administration of a genetic delivery platform.

These questions place in vivo CAR‑T at the intersection of multiple advanced therapy regulatory frameworks.

FDA Regulatory Framework

In the United States, in vivo CAR‑T therapies are currently regulated primarily through broader gene therapy and cellular immunotherapy frameworks.

 In the United States, these products are expected to fall under the oversight of the FDA’s Center for Biologics Evaluation and Research (CBER), including the Office of Therapeutic Products (OTP), depending on product characteristics and mechanism of action.

Several existing FDA guidance documents are highly relevant to cellular therapy, gene therapy, genome editing, and advanced biologics are highly applicable to in vivo CAR‑T development, including:
• Considerations for the Development of Chimeric Antigen Receptor (CAR) T Cell Products
• Human Gene Therapy for Rare Diseases
• CMC Information for Human Gene Therapy IND Applications
• Long Term Follow‑Up After Administration of Human Gene Therapy Products
•  Human Gene Therapy Products Incorporating Human Genome Editing

Considerations for the Design of Early-Phase Clinical Trials of Cellular and Gene Therapy Products

Testing of Retroviral Vector-Based Human Gene Therapy Products for Replication Competent Retrovirus During Product Manufacture and Patient Follow-up. The FDA views many in vivo CAR‑T platforms as particularly high‑risk because they involve systemic delivery of genetic material capable of reprogramming immune cells within the body.

Biodistribution and Off‑Target Risk

One of the central regulatory concerns for in vivo CAR‑T therapies is biodistribution.

Unlike ex vivo CAR‑T therapies, where genetically modified cells are characterised before administration, in vivo approaches rely on delivery systems that distribute through the patient’s body after dosing.

Off‑target transduction into hepatocytes, macrophages, stem cells, or central nervous system tissues could create substantial safety risks depending on the therapeutic construct involved.

Quantitative PCR assays, tissue distribution models, in vivo imaging, and vector persistence studies are becoming increasingly important components of regulatory submissions.

Regulation of Viral Vector Platforms

Many in vivo CAR‑T platforms utilise viral vectors such as lentiviral or adeno-associated viral (AAV) systems.

Regulators require extensive characterisation of these vectors, including:
• Replication competence testing
• Vector genome integrity
• Transgene expression control
• Capsid characterisation
• Manufacturing consistency
• Shedding risk assessment
• Immunogenicity profiling

Lentiviral vectors attract particular scrutiny because of their ability to integrate into the host genome.
Although integration may support durable CAR expression, it also raises concerns regarding:
• Insertional mutagenesis
• Clonal expansion
• Secondary malignancies
• Long‑term genomic instability

As a result, long‑term patient monitoring requirements may extend for many years after treatment.

Lipid Nanoparticles and Non‑Viral Systems

Non‑viral delivery systems, particularly lipid nanoparticles (LNPs), are attracting significant regulatory interest because they may avoid some limitations associated with viral vectors.

LNP systems can deliver messenger RNA encoding CAR constructs without permanent genomic integration.

From a regulatory perspective, transient expression systems may offer advantages because:
• CAR activity can diminish over time
• Long‑term integration risks are reduced
• Repeat dosing strategies may become possible
• Manufacturing may be simplified

However, regulators still require detailed assessment of:
• Nanoparticle composition
• Encapsulation efficiency
• Particle size distribution
• Stability
• Endosomal escape efficiency
• Systemic inflammatory responses
• Biodistribution characteristics

The rapid emergence of mRNA and nanoparticle therapeutics is driving regulators to adapt traditional biologics frameworks to more dynamic delivery technologies.

Genome Editing and CRISPR‑Based Systems

Some next generation in vivo CAR‑T platforms incorporate CRISPR or other genome editing systems to engineer immune cells directly inside the patient.

These technologies create additional regulatory complexity because they involve active genomic modification in vivo.

Regulators are particularly focused on:
• Off‑target editing
• Chromosomal rearrangements
• Large genomic deletions
• Integration events
• Genotoxicity
• Mosaic editing patterns

Advanced sequencing technologies are increasingly required to characterise genomic editing outcomes.

Sponsors may also need to demonstrate:
• Editing specificity
• Editing durability
• Tissue selectivity
• Functional consequences of unintended edits

As genome editing technologies continue to evolve, regulators are likely to increase expectations for genomic safety characterisation.

The Future of Regulation for Programmable Immune Therapies

Regulatory science is evolving rapidly alongside the technologies themselves.

Traditional pharmaceutical frameworks were not designed for therapies capable of dynamically programming immune cells inside the body.

Future regulatory systems may increasingly treat programmable immune engineering platforms as distinct therapeutic categories requiring specialised evaluation methodologies.

As the science matures, regulators will likely focus not only on product safety and efficacy, but also on controllability, predictability, delivery precision, and long‑term systems biology effects.

The field is still in its infancy, but in vivo CAR‑T therapies are already reshaping how regulators think about the future of advanced medicine. Regulatory expectations for these therapies continue to evolve rapidly and may vary depending on product design, delivery platform, manufacturing approach, and jurisdiction. Early regulatory strategy and platform-specific assessment are increasingly important in supporting efficient development pathways.

This paper reflects current regulatory thinking at the time of publication and is intended for general informational purposes only.

Further reading:

Featured Post

Regulatory Strategy for Drug and Device Development

Regulatory Strategy for Drug and Device Development. Why it must start on Day One […]

February 24, 2026

·

Adjutor

 

Featured Post

Cell and Gene Therapies Regulation

Navigating the Regulation of Cell and Gene Therapies in Australia and New Zealand […]

October 23, 2024

·

Adjutor